Prothena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint

MT Newswires Live

Dec 19, 2024

Prothena (PRTA) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.

However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.

The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.

Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.

Prothena's share price fell over 6% in recent premarket activity Thursday.

Price: 11.21, Change: -0.74, Percent Change: -6.19

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2492126946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492126946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492126946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492126946","market":"fut","top_or_hot":-1,"title":"Prothena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> Prothena (PRTA) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.</p><p>However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.</p><p>The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.</p><p>Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.</p><p>Prothena's share price fell over 6% in recent premarket activity Thursday.</p><p>Price: 11.21, Change: -0.74, Percent Change: -6.19</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prothena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProthena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-19 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Prothena (PRTA) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.</p><p>However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.</p><p>The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.</p><p>Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.</p><p>Prothena's share price fell over 6% in recent premarket activity Thursday.</p><p>Price: 11.21, Change: -0.74, Percent Change: -6.19</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492126946","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492126946","pubTimestamp":1734608821,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Prothena  said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.Prothena's share price fell over 6% in recent premarket activity Thursday.Price: 11.21, Change: -0.74, Percent Change: -6.19","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SSI":"Stage Stores Inc","PRTA":"Prothena Corporation plc"},"translate_title":"Prothena表示评估Prasinezumab治疗早期帕金森病的研究错过了主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTA":0.9,"SSI":1},"content_text":"Prothena (PRTA) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.Prothena's share price fell over 6% in recent premarket activity Thursday.Price: 11.21, Change: -0.74, Percent Change: -6.19","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}